What is the recommended dosing regimen of Diclectin (doxylamine succinate + pyridoxine) for nausea and vomiting in pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Diclectin Dosing for Nausea and Vomiting of Pregnancy

Start with 2 tablets (doxylamine 10mg/pyridoxine 10mg each) at bedtime, and titrate up to a maximum of 4 tablets daily based on symptom control 1.

Initial Dosing Regimen

Begin with 2 tablets at bedtime (total: doxylamine 20mg/pyridoxine 20mg). This is the FDA-approved starting dose for Diclectin/Diclegis 1.

Dose Titration Algorithm

If symptoms persist after starting the bedtime dose, escalate systematically:

  • Day 1-2: 2 tablets at bedtime
  • If inadequate control: Add 1 tablet in the morning (total: 3 tablets daily)
  • If still inadequate: Add 1 tablet mid-afternoon (total: 4 tablets daily - 1 morning, 1 mid-afternoon, 2 at bedtime)

Maximum dose: 4 tablets daily 1, 2.

The 2024 RCOG Green-top Guideline confirms this as first-line therapy, recommending "Doxylamine and Pyridoxine 20/20mg PO at night, increase to additional 10/10mg in morning and 10/10mg at lunchtime if required" 2. This aligns precisely with the FDA labeling.

Critical Dosing Considerations

Most women are significantly underdosed. A prospective study found that 50 of 68 women with moderate-to-severe NVP were receiving only 2 tablets daily instead of the recommended 4 tablets 3. When doses were appropriately increased to 4 tablets daily, there was significant improvement in nausea duration (4 to 3 hours, p<0.001), vomiting frequency (1.6 to 1.3 episodes/day, p=0.02), and overall PUQE scores (7.5 to 6.1, p<0.001) 3.

Higher doses are safe when needed. Evidence demonstrates that doses exceeding the standard 4 tablets daily (calculated per kg body weight) do not increase maternal adverse effects or affect pregnancy outcomes 4. Women weighing more or with severe symptoms may require individualized dosing above the standard maximum, though this should be done cautiously and with close monitoring.

Safety Profile

The combination is well-tolerated with no increased adverse events compared to placebo in randomized trials 5. The most common side effect is somnolence (>5%), which is why the largest dose is given at bedtime 1.

Key warnings:

  • Avoid driving or operating machinery until you know how the medication affects you 1
  • Do not combine with alcohol or other CNS depressants 1
  • Use caution in patients with narrow-angle glaucoma, urinary retention, or peptic ulcer disease due to anticholinergic effects 1
  • May interfere with urine drug screens for methadone, opiates, and PCP 1

Clinical Context

Diclectin/Diclegis is recommended as first-line pharmacotherapy for NVP when conservative measures (dietary modifications, ginger) fail 2. The 2024 RCOG guideline gives this Grade A evidence support 2. It should be prescribed early to prevent progression to hyperemesis gravidarum, which is more difficult to treat and may require hospitalization 6.

If symptoms remain uncontrolled on maximum doses of doxylamine-pyridoxine, escalate to second-line agents such as metoclopramide or ondansetron rather than continuing inadequate therapy 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.